Lipids, Apolipoproteins, Lipid‐Lowering Drugs, and the Risk of Cerebral Small Vessel Disease: A Mendelian Randomization Study
The present Mendelian randomization study indicates that genetically determined hyperlipidemia is closely associated with a higher risk of cerebral small vessel disease, especially SVS. Lipid-lowering drugs could be potentially considered for the therapies and preventions of SVS rather than WMH.
Authors
- Wensheng Qu (ORCID: https://orcid.org/0000-0002-8518-1159)
- Shuai Liu (ORCID: https://orcid.org/0000-0002-8405-6743)
- Minghuan Wang (ORCID: https://orcid.org/0000-0003-2879-5741)
- Hao Huang (ORCID: https://orcid.org/0000-0003-1748-1245)
- Xiang Luo (ORCID: https://orcid.org/0000-0001-9233-5788)
- Wei Wang (ORCID: https://orcid.org/0000-0002-9176-5150)
- Xinyue Wang (ORCID: https://orcid.org/0000-0003-4231-617X)
- Zhiyuan Yu (ORCID: https://orcid.org/0000-0001-6157-3986)
- Yi Xie (ORCID: https://orcid.org/0009-0003-3485-6843)
Institutions
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2024-08-19
- DOI
- https://doi.org/10.1161/jaha.123.032409
- Citations
- 13
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 7.45